| human | Q5 |
| P2456 | DBLP author ID | 31/7049 |
| P1960 | Google Scholar author ID | _qIeoKUAAAAJ |
| P269 | IdRef ID | 087819163 |
| P10058 | IRIS UNIBO author ID | 123630 |
| P10762 | IRIS UNIMORE author ID | 09009 |
| P10055 | IRIS Verona author ID | 32290 |
| P2798 | Loop ID | 567162 |
| P1207 | NUKAT ID | n2006144097 |
| P496 | ORCID iD | 0000-0001-5637-8983 |
| P11597 | Padua Research Archive author ID | 94196 |
| P3829 | Publons author ID | 2521857 |
| P1053 | ResearcherID | G-6922-2014 |
| P1153 | Scopus author ID | 36049476400 |
| P10013 | SNSF person ID | 524354 |
| P214 | VIAF ID | 23983937 |
| P2002 | X username | frbertoni |
| P69 | educated at | University of Milan | Q46210 |
| P108 | employer | UCL Institute of Child Health | Q7864075 |
| San Raffaele Hospital | Q3145229 | ||
| Mario Negri Institute for Pharmacological Research | Q3803751 | ||
| Barts and The London School of Medicine and Dentistry | Q4120330 | ||
| Ospedale Regionale di Locarno | Q30280583 | ||
| Istituto Oncologico della Svizzera Italiana | Q30280648 | ||
| Ospedale Maggiore Policlinico | Q52842358 | ||
| P734 | family name | Bertoni | Q21491278 |
| Bertoni | Q21491278 | ||
| Bertoni | Q21491278 | ||
| P735 | given name | Francesco | Q2268455 |
| Francesco | Q2268455 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q47934995 | A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect |
| Q42767063 | A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression |
| Q33399582 | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma |
| Q46093830 | A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. |
| Q36893709 | A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation |
| Q33450339 | A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals |
| Q46439057 | ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. |
| Q112575987 | ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma |
| Q82973367 | Absence of NOTCH1 gene mutations in MALT lymphomas |
| Q52615711 | Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. |
| Q33605291 | An integrated Bayesian analysis of LOH and copy number data. |
| Q53811493 | An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. |
| Q73245508 | Analysis of BCL-10 gene mutations in ovarian cancer cell lines |
| Q27851655 | Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation |
| Q46008254 | Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. |
| Q37866541 | Anaplastic lymphoma kinase in human cancer |
| Q43419517 | Another Piece of the MALT Lymphomas Jigsaw. |
| Q50201496 | Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines |
| Q73747864 | Association of gastric and Waldeyer's ring lymphoma: a molecular study |
| Q37837955 | B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage |
| Q60609610 | BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome |
| Q47269674 | BET Proteins as Targets for Anticancer Treatment |
| Q33398657 | Bayesian DNA copy number analysis |
| Q80573560 | Bendamustine in lymphomas: more to combine? |
| Q38106810 | Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma |
| Q59797089 | Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma |
| Q39520264 | Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. |
| Q78197987 | CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers |
| Q36545701 | Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736 |
| Q43417673 | Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? |
| Q37848452 | Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. |
| Q39573664 | Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. |
| Q82779325 | Chromosome band 6q deletion pattern in malignant lymphomas |
| Q80559624 | Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type |
| Q46102733 | Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. |
| Q73922851 | Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma |
| Q34287747 | Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma |
| Q36422362 | Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. |
| Q74484111 | Clonality assessment in blood of patients with mantle cell lymphoma |
| Q39933783 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. |
| Q61906657 | Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas |
| Q28290391 | Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma |
| Q58010717 | Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma |
| Q38887338 | Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. |
| Q90317678 | Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified |
| Q53568928 | Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. |
| Q91832272 | DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas |
| Q35561291 | DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features |
| Q44754728 | Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype |
| Q40899317 | Delving deeper into MALT lymphoma biology |
| Q45280589 | Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma |
| Q48359090 | Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study |
| Q44483495 | Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. |
| Q30701692 | Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices |
| Q52621343 | Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. |
| Q60596976 | Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia |
| Q112298195 | Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer |
| Q54689358 | Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). |
| Q51803736 | Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. |
| Q38889427 | Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. |
| Q58000969 | Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features |
| Q47835724 | Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reaction |
| Q44479607 | Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis |
| Q58011085 | Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP |
| Q45150144 | Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice |
| Q28215110 | Genetic alterations underlying the pathogenesis of MALT lymphoma |
| Q91723445 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma |
| Q35974341 | Genetic lesions in diffuse large B-cell lymphomas |
| Q44644345 | Genome wide DNA-profiling of HIV-related B-cell lymphomas |
| Q58001017 | Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion |
| Q51548976 | Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. |
| Q64949719 | Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. |
| Q44927889 | Genome-wide DNA profiling of HIV-related B-cell lymphomas |
| Q58000950 | Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome |
| Q37636972 | Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma |
| Q45223072 | Genome-wide high resolution DNA profiling of hairy cell leukaemia |
| Q61799198 | Genome-wide promoter methylation of hairy cell leukemia |
| Q59647705 | Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma |
| Q40330626 | Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma |
| Q42919408 | Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. |
| Q35082540 | Genomic profiles of MALT lymphomas: variability across anatomical sites |
| Q58000971 | Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas |
| Q93270073 | HMGA1-pseudogene7 transgenic mice develop B cell lymphomas |
| Q80790789 | Hematological Oncology: further ahead |
| Q33695841 | Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. |
| Q54538115 | High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. |
| Q41326723 | Histologic transformation in marginal zone lymphomas†. |
| Q93222571 | IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies |
| Q58000974 | IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia |
| Q35814897 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia |
| Q49186472 | IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. |
| Q34284639 | Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma |
| Q40436099 | Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts |
| Q34388453 | Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. |
| Q44425120 | IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome |
| Q58000976 | Immunogenetics features and genomic lesions in splenic marginal zone lymphoma |
| Q48049038 | Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process |
| Q75242505 | Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research |
| Q73307419 | Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma |
| Q56779381 | Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis |
| Q38717603 | Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. |
| Q40430809 | In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. |
| Q90656551 | In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas |
| Q54603185 | In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. |
| Q45286370 | Incidence, risk factors and outcome of histological transformation in follicular lymphoma |
| Q89347561 | Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation |
| Q92372459 | Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma |
| Q58000927 | Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array |
| Q90185598 | Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog |
| Q28394721 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia |
| Q51490388 | Integrated profiling of diffuse large B-cell lymphoma with 7q gain. |
| Q61039259 | Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| Q53220555 | Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. |
| Q36110261 | Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma |
| Q37588785 | Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance |
| Q89599313 | Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? |
| Q44052389 | Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. |
| Q47805148 | Let's give BACH2 a breath of fresh air. |
| Q41370330 | Life expectancy of young adults with follicular lymphoma |
| Q90225791 | Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization |
| Q83297043 | Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type |
| Q37860344 | Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. |
| Q46755084 | MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia |
| Q87141220 | MYC network mutations in high-risk chronic lymphocytic leukaemia |
| Q84233301 | MYD88 somatic mutations in MALT lymphomas |
| Q81019854 | Mantle cell lymphoma |
| Q34999329 | Mantle cell lymphoma: new treatments targeted to the biology. |
| Q104131585 | Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes |
| Q38910690 | Methylation patterns in marginal zone lymphoma |
| Q48039699 | Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. |
| Q58001001 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study |
| Q54387895 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. |
| Q40083717 | Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. |
| Q40195859 | Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. |
| Q43918537 | Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial |
| Q33747256 | Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. |
| Q52614373 | Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. |
| Q44078664 | Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia |
| Q42120007 | Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. |
| Q59647713 | Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas |
| Q34277639 | Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. |
| Q29013141 | Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness |
| Q52018506 | Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. |
| Q84139912 | Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms |
| Q34497376 | Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. |
| Q37705651 | OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations |
| Q36994829 | Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy |
| Q40033549 | Oncogenic BARD1 isoforms expressed in gynecological cancers |
| Q38651621 | PCSF: An R-package for network-based interpretation of high-throughput data. |
| Q47608454 | PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. |
| Q39100309 | PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma |
| Q38239219 | PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas |
| Q51767765 | Patterns of survival of follicular lymphomas at a single institution through three decades. |
| Q60609607 | Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells |
| Q46474270 | Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. |
| Q62494644 | Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals |
| Q38707684 | Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. |
| Q91799998 | Primary central nervous system lymphoma: Novel precision therapies |
| Q73058096 | Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials |
| Q50798505 | Prognostic impact of monocyte count at presentation in mantle cell lymphoma. |
| Q47739621 | Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma |
| Q57571459 | Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas |
| Q45755070 | Risk factors of central nervous system relapse in mantle cell lymphoma |
| Q97565945 | Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type |
| Q90119815 | STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma |
| Q54365359 | Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. |
| Q56995316 | Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases |
| Q92247784 | Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas |
| Q58010868 | Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma |
| Q48107591 | Staining the target: CD37 expression in lymphomas |
| Q36254660 | State-of-the-art therapeutics: marginal-zone lymphoma. |
| Q58001002 | Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome |
| Q29048186 | Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma |
| Q60609608 | Syk expression patterns differ among B-cell lymphomas |
| Q47607631 | TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line |
| Q38916281 | The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. |
| Q92640679 | The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents |
| Q53014079 | The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. |
| Q37201887 | The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. |
| Q92544485 | The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax |
| Q36851684 | The cellular origin of mantle cell lymphoma. |
| Q38098774 | The changing paradigm of chronic lymphocytic leukemia management. |
| Q44047939 | The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. |
| Q60197171 | The clinical and biological features of a series of immunophenotypic variant of B-CLL |
| Q36193517 | The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development |
| Q51609722 | The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. |
| Q37243257 | The genetics of nodal marginal zone lymphoma |
| Q38847105 | The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. |
| Q46490525 | The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors |
| Q38779313 | The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance |
| Q50878921 | The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells. |
| Q38264349 | The transcription factor ETS1 in lymphomas: friend or foe? |
| Q38409231 | Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes |
| Q46607983 | Toward new treatments for mantle-cell lymphoma? |
| Q52611046 | Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. |
| Q37768456 | Treatment of gastric marginal zone lymphoma of MALT type. |
| Q44629915 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. |
| Q35153215 | Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. |
| Q33350941 | Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. |
| Q60303682 | Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach |
| Q91557800 | Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified |
| Q54502320 | Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. |
Search more.